SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?


To: Steve Lokness who wrote (658)4/18/1998 3:18:00 PM
From: Richard Haugland  Read Replies (1) | Respond to of 1728
 
Steve: AFFX shot up just at the end again Friday from 30 to 31 before closing at 30 1/2 whereas VGINF shot down. I sold some VGINF earlier in the week at 9 3/8 and 9 1/2 and have been buying AFFX at ~30 and selling it again at ~31. I plan to buy some VGINF back at a lower price, if it descends, as in the past because I expect its earnings report to be quite optimistic, even if its net earnings are still negative. Just missed selling the AFFX late Friday I bought on Wednesday. Unfortunately I was out when it rose from about 31 to over 35 but then I was also out while it came back below 31 (except one profitable day trade).

I am really too heavy in genetic (and other) screening now with AFFX, MLNM, ABSC, MDYN, VGINF and VYSI (Vysis) stock with this being >50% of my portfolios (mostly because I have been buying MLNM as it continues to descend). VYSI, which is newly public, looks good in a fairly short period (a few years to profitability at the most). VYSI just won a major case from Oncor that sustained its licensed patents (from U Ca) in Fluorescence in situ Hybridization (FISH) and it has several products either approved or in the pipeline. VYSI also got royalties from Oncor, the non-oncology business from Oncor (~$3,000,000 revenues a year) and $3,000,000 dollars (probably minus the pile its lawyers will get). It was started at AMOCO, which still owns a fair amount of stock. The stock initially sold at $12 and has descended to about $10.50. Few people watch it so far, I believe.

My other BIO holding is ENMD, which suddenly moved from $12 (low of 11 3/8 intraday) to $13 on Friday on relatively high volume (4x normal), with the last half dollar in the last 2 minutes (through my sell day-order for some shares at 12 3/4). According to a friend at Mayo whom I trust, their products under development (tumor treatment drugs) are extremely promising if they can scale up production and are being given expedited evaluation at the NIH.